Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disabling receptor ensembles with rationally designed interface peptidomimetics.

Alan Berezov1, Jinqiu Chen, Qingdu Liu

  • 1Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine and the Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania 19104, USA.

The Journal of Biological Chemistry
|May 16, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

OTUD5-TIF1γ-SMAD3/4 positive feedback loop inhibits TGF-β-induced EMT and metastasis in NSCLC.

Cell death & disease·2026
Same author

Emergence of spatiotemporal patterns beyond Turing-Hopf bifurcation in semi-arid vegetation systems.

Mathematical biosciences·2026
Same author

Breast cancer recurrence risk prediction based on MIL.

Frontiers in medicine·2026
Same author

Clinical Study on Four- versus Two-Hour Hemoadsorption Combined with Hemodialysis for Enhanced Clearance of Protein-Bound Uremic Toxins in Maintenance Hemodialysis Patients.

Blood purification·2026
Same author

SRC-mediated phosphorylation of UBC9 regulates inflammatory and metabolic signaling in alcohol-associated liver disease.

Science advances·2026
Same author

STAT3-mediated transactivation of NOVA2 promotes lung adenocarcinoma metastasis by splicing SMAD4.

Oncogene·2026

Researchers designed erbB peptides to block dimerization of erbB receptor tyrosine kinases, crucial for cancer signaling. These peptides selectively bind receptors, inhibit dimerization, and reduce cancer cell growth, offering potential therapeutic strategies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • The erbB family of receptor tyrosine kinases (erbB1-4) are frequently overexpressed in human cancers.
  • Receptor dimerization is essential for erbB-mediated signaling pathways.
  • Targeting these dimerization events offers a strategy for cancer therapy.

Purpose of the Study:

  • To design and characterize peptides that inhibit erbB receptor dimerization.
  • To investigate the role of specific extracellular domains in receptor self-association.
  • To evaluate the therapeutic potential of dimerization inhibitors in cancer models.

Main Methods:

  • Design of peptides based on predicted dimerization interfaces in erbB receptor subdomain IV.
  • Surface plasmon resonance (BIAcore) assays to assess peptide binding affinity and specificity.

Related Experiment Videos

  • Cell-based assays (MTT, viability) to evaluate the effect of peptides on cancer cell growth and receptor dimerization.

    • Main Results:

    • Designed erbB peptides selectively bind erbB receptor ectodomains and subdomain IV of erbB2 with submicromolar affinity.
    • Peptides inhibit heregulin-induced erbB3 interactions and dose-dependently block erbB receptor dimerization in transfected cell lines.
    • The peptides effectively inhibited the growth of T6-17 and 32D cancer cells overexpressing erbB receptors.

    Conclusions:

    • Distinct loops in subdomain IV are identified as key receptor-receptor interaction sites.
    • Structure-based targeting of dimerization interfaces can disable erbB receptor activity.
    • These erbB peptides serve as valuable probes for signaling pathways and potential therapeutic agents for cancer.